Compare Abbott Laboratories (ABT) vs Genuine Parts Company (GPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Genuine Parts Company — how do they compare? Abbott Laboratories trades at $95.24 (market cap $166.94B), while Genuine Parts Company trades at $124.94 (market cap $17.71B). The key difference: Abbott Laboratories is far larger — about 9.4× Genuine Parts Company's market cap, and Genuine Parts Company pays the higher dividend (3.3%). Which is the better fit depends on your goals.
| ABT | GPC | |
|---|---|---|
Market Cap | $166.94B | $17.71B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $149.26 |
52-Week Low | $82.57 | $92.47 |
Enterprise Value | $193.69B | $23.92B |
Dividend Yield | 2.63% | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
GPC trades at $128.67, down 2.94% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed earnings, missing in Q3 and Q4 2025 but beating in Q1 2026, with Q2 2026 results due July 21, 2026. Financials show revenue growth to $24.3B in 2025 but a sharp decline in net income margin to 0.24%, while the P/E ratio of 292.41 reflects high valuation relative to earnings. A dividend of $1.06 per share is scheduled for payment on July 2, 2026.
The outlook is cautious due to weak profitability and high P/E, but analyst consensus is a Buy with a $133 price target, suggesting modest upside. Risks include earnings volatility and competitive pressures in the automotive parts sector. The stock's near-term direction hinges on Q2 2026 earnings, with support at $126 and resistance at $131.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
